Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine in Dravet Syndrome
NCT02682927Phase 3Completed
- Sponsor
- Zogenix, Inc.
- Start
- Jan 2016
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in Dravet syndrome (3 arms), sponsored by Zogenix, Inc. Primary endpoint: Mean Convulsive Seizure Frequency at 14 weeks. Started Jan 2016; status: completed.
02
Drugs
fenfluramine
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT02682927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02682927.